EMA Authorised: Akeega (abiraterone acetate;niraparib (tosilate monohydrate))

View source ↗

Summary

Akeega, containing abiraterone acetate and niraparib tosilate monohydrate, has been authorised for castration-resistant prostatic neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostatic Neoplasms Castration-resistant

Drugs mentioned

• AKEEGA (niraparib tosylate monohydrate and abiraterone acetate)
• Abiraterone acetate (Abiraterone acetate)
• niraparib (tosilate monohydrate) (niraparib tosilate monohydrate)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms, Castration-Resistant. Decision date: 14/08/2026